Pyxis Oncology Inc (PYXS)
Healthcare
Biotechnology
2.70 $
-7.7%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Pyxis Oncology Inc (PYXS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 58.8% of the shares are freely tradable; institutional investors hold 33.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
33.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
22.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
58.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
4.3%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
63Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Pfizer Inc | 11.10 | 7,032,770 | +0.0 | 03/31/2026 |
| LAURION CAPITAL MANAGEMENT LP | 7.89 | 4,997,333 | +4.2 | 03/31/2026 |
| GordonMD Global Investments LP | 6.51 | 4,121,870 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 3.69 | 2,335,768 | +7.9 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.21 | 2,033,510 | +0.0 | 03/31/2026 |
| Palo Alto Investors, LLC | 1.60 | 1,010,510 | -2.6 | 03/31/2026 |
| 683 Capital Management LLC | 1.41 | 896,263 | +0.5 | 03/31/2026 |
| Renaissance Technologies Corp | 1.40 | 888,680 | +22.0 | 03/31/2026 |
| BlackRock Inc | 1.25 | 788,839 | +0.6 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.24 | 1,422,296 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.